Clinical trials: Schizophrenia, open to volunteers
Cannabis Use, SCHIZOPHRENIA
Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia
The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis.
- Conditions
- Cannabis Use, SCHIZOPHRENIA, Psychosis, rTMS
- Trial name
- NCT07196462
- Testing
- 3 Minute iTBS to the L DLPFC, One-Minute, Personalized, DMN Targeted CTBS
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Cardiovascular Side Effects of Clozapine, Neutropenia Due to Clozapine
Nor)Clozapine Kinetics and Side Effects in Therapy Resistant Schizophrenia and the Optimal Sampling Time for Therapeutic Drug Monitoring
The goal of this observational study is to better understand how clozapine treatment can be tailored as regards minimizing side effects and optimizing efficacy and monitoring.
- Conditions
- Cardiovascular Side Effects of Clozapine, Neutropenia Due to Clozapine, General Side Effects of Clozapine, Constipation Due to Clozapine
- Trial name
- COTTONS (NCT06749041)
- Volunteers
- 60 people
- Sponsor
- GGZ Noord-Holland-Noord
SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia
This study is a confirmatory, double-blind, placebo-controlled randomized clinical trial (RCT) testing whether gamma EEG neurofeedback (EEG-NFB) improves working memory in adults with schizophrenia or schizoaffective disorder.
- Trial name
- NCT07592169
- Testing
- EEG Neurofeedback
- Volunteers
- 104 people
- Sponsor
- University of California, San Diego
Psychosis
Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis
Chronic psychosis, including schizophrenia is now viewed as a progressive disorder where cognitive deficits predate the clinical onset.
- Trial name
- PSYCARE (NCT05796401)
- Testing
- Cognitive training, Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC, Treatment as usual (TAU)
- Where
- 13 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia, Schizoaffecitve Disorder
Digital Therapeutics for Social Cognitive Function in Schizophrenia Spectrum Disorder
The purpose of this study is to evaluate the safety and preliminary effectiveness of a smartphone-based digital therapeutic application (AffectUs) for improving social cognition, particularly emotion processing and social cue…
- Trial name
- NCT07755605
- Testing
- Digital therapeutic (AffectUs), Psychoeducational materials
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Bipolar I Disorder, Bipolar II Disorder
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
The goal of this clinical trial is to identify the specific characteristics (phenotypes) that may be useful to help select the right medication for weight loss, and to study the effect of individualized guided medication in…
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity
- Trial name
- OBOE-Mayo (NCT07213466)
- Testing
- Group Therapy Program, semaglutide, Phentermine-Topiramate
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Schizophrenia, Cognitive Functions
The Effect of Combined Brain Stimulation and Exercise for Improving Cognitive Function in Schizophrenia
The study will investigate the (1) additive and synergistic effects of tDCS and aerobic exercise on cognitive function and clinical symptoms in schizophrenia, and (2) neurophysiological mechanisms (mediators) underlying these…
- Trial name
- NCT07745140
- Testing
- Aerobic exercise, Active tDCS
- Where
- Hong Kong
- Volunteers
- 66 people
- Sponsor
- The Hong Kong Polytechnic University
Negative Symptoms in Schizophrenia, Brain Stimulation Intervention
Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
Dysfunction of the dorsolateral prefrontal cortex (DLPFC) is central to the persistence of negative symptoms in schizophrenia. Both HD-tDCS and iTBS targeting the left DLPFC have shown therapeutic benefit.
- Trial name
- NCT07680959
- Testing
- active iTBS followed by active HD-tDCS
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Prodromal Schizophrenia
Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis
The Ohio State University Early Psychosis Intervention Center is implementing a specialized clinical program to serve individuals who meet clinical high risk criteria for a psychosis.
- Trial name
- NCT03970005
- Testing
- Step-Based Care Model
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ohio State University
Schizophrenia and Related Disorders
Bilateral Prefrontal and Insular TMS for Depression in Schizophrenia
The purpose of this study is to provide an effective repetitive transcranial magnetic stimulation (rTMS) treatment for depressive symptoms in patients with schizophrenia.
- Trial name
- NCT07060066
- Testing
- Active rTMS stimulation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
This will be a multicenter, randomized, double-blind, placebo and active comparator parallel-controlled study designed to assess the safety and efficacy of VV119 (2.0 to 6.0 mg) for the treatment of adult participants diagnosed…
- Trial name
- NCT07703956
- Testing
- VV119 2mg, VV119 4mg, VV119 6mg
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Vigonvita Life Sciences
Psychosis, SCHIZOPHRENIA 1 (Disorder)
Developing a Virtual Reality-assisted Intervention for Emotion Regulation Difficulties in Psychosis
Supporting people with psychosis to manage their emotions using virtual reality Many people who have experienced psychosis feel overwhelmed by their emotions. Emotions get in the way of doing what matters to them.
- Conditions
- Psychosis, SCHIZOPHRENIA 1 (Disorder), Schizophrenia and Related Disorders
- Trial name
- MANOEUVRE (NCT07623928)
- Testing
- MANOEUVRE therapy
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- King's College London
Psychotic Disorder
Speech-based Assessment of Relapse Risk in People With Psychosis
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis.
- Trial name
- TRUSTING-WP4 (NCT07397975)
- Testing
- Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
- Where
- 7 sites in Czechia, Ireland and 4 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Philipp Homan
SCHIZOPHRENIA 1 (Disorder), Psychosocial Adaptation
The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia
The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia.
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Psychosocial Adaptation, Treatment Adherence
- Trial name
- NCT07144592
- Testing
- solution-oriented approach program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Muş Alparslan University
Serious Mental Illness, Schizophrenia
Mindfulness-Based Therapy for Serious Mental Illness
Serious mental illness (SMI), encompassing schizophrenia-spectrum and major mood disorders, has been estimated to affect approximately 5.4% of the U.S. adult population each year.
- Conditions
- Serious Mental Illness, Schizophrenia, Major Depressive Disorder, Bipolar Disorder
- Trial name
- MBT (NCT06880796)
- Testing
- Mindfulness-based therapy, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Butler Hospital
Schizophrenia, Bipolar Disorder
Approaches For ThE pRioritization of Patients in priMAry Care Post-COVID To Reduce Health Inequities (AFTERMATH)
The COVID-19 pandemic significantly impacted primary care across Canada. Inequities in prevention activities and chronic disease management likely increased but the extent is unknown.
- Trial name
- AFTERMATH (NCT05823805)
- Testing
- Community Health Worker
- Volunteers
- 520 people
- Sponsor
- Unity Health Toronto
SCHIZOPHRENIA 1 (Disorder), Schizotypal Disorder
PS-Trauma - Development of Trauma Treatment for Patients With Co-morbid Psychotic Disorders and Traumas
Overview: People with psychotic disorders frequently have a history of traumatic events such as neglect, bullying, or physical and sexual abuse.
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizotypal Disorder, Post Traumatic Stress Symptoms
- Trial name
- PS-Trauma (NCT07242586)
- Testing
- Prolonged Exposure, EMDR
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Nikolai Albert
Schizophrenia Patients, Psychoeducation
The Effect of Psychosocial Skills Focused Group Psychoeducation in Schizophrenia Patients
The aim of this study was to evaluate the effect of psychosocial skills-oriented group psychoeducation on functional recovery, treatment adherence and mental well-being in patients with schizophrenia.
- Conditions
- Schizophrenia Patients, Psychoeducation, Functional Status, Treatment Outcome
- Trial name
- Schizophrenia (NCT06872424)
- Testing
- psychosocial skills-oriented group psychoeducation
- Volunteers
- 34 people
- Sponsor
- Gazi University
Schizophrenia, Schizo Affective Disorder
Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA
A new mental health application will be developed for persons with schizophrenia and schizoaffective disorder. The aim is to look at whether it is feasible to use a mobile health application for improving medication adherence in…
- Trial name
- NCT06474325
- Testing
- Intervention via mobile application
- Where
- India
- Volunteers
- 44 people
- Sponsor
- University of Pittsburgh
Schizophrenia
A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia
This study is designed to assess the safety and tolerability of the effects of XEP527, with particular emphasis on disease status and its compatibility with the standard of care in patients with stable schizophrenia.
- Trial name
- NCT07908680
- Testing
- XEP527
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals